LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Under the terms of the agreement, LianBio is entitled to receive a total consideration of $350 million.
- Under the terms of the agreement, LianBio is entitled to receive a total consideration of $350 million.
- In July 2023, LianBio entered into a clinical supply agreement with AstraZeneca in China to procure osimertinib for this clinical trial.
- In October 2023, LianBio announced that the company’s Board of Directors initiated a comprehensive strategic review of the company, with an update anticipated in the first half of 2024.
- Cash, cash equivalents, marketable securities and restricted cash at September 30, 2023 totaled $252.2 million compared to $302.4 million as of December 31, 2022.